M

Medicofarma Biotech SA
WSE:MDB

Watchlist Manager
Medicofarma Biotech SA
WSE:MDB
Watchlist
Price: 0.377 PLN -2.08% Market Closed
Market Cap: 25.6m PLN
Have any thoughts about
Medicofarma Biotech SA?
Write Note

Medicofarma Biotech SA
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Medicofarma Biotech SA
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
M
Medicofarma Biotech SA
WSE:MDB
Net Income (Common)
-zł2.7m
CAGR 3-Years
-43%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
Inno-Gene SA
WSE:IGN
Net Income (Common)
-zł6.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-24%
R
Ryvu Therapeutics SA
WSE:RVU
Net Income (Common)
-zł104.1m
CAGR 3-Years
-13%
CAGR 5-Years
-22%
CAGR 10-Years
N/A
S
Selvita SA
WSE:SLV
Net Income (Common)
zł47.4m
CAGR 3-Years
37%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Medicofarma Biotech SA
Glance View

Market Cap
25.6m PLN
Industry
Life Sciences Tools & Services

Medicofarma Biotech SA is a biotechnology company, which focuses on the innovative medicine, medicinal products, and biotechnology products. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2008-11-27. The company is engaged in works on drugs, medical devices and biotechnological products. It's research and development works are carried out in laboratories in Lublin and Poznan.

MDB Intrinsic Value
0.096 PLN
Overvaluation 75%
Intrinsic Value
Price
M

See Also

What is Medicofarma Biotech SA's Net Income (Common)?
Net Income (Common)
-2.7m PLN

Based on the financial report for Dec 31, 2023, Medicofarma Biotech SA's Net Income (Common) amounts to -2.7m PLN.

What is Medicofarma Biotech SA's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
-43%

Over the last year, the Net Income (Common) growth was -68%. The average annual Net Income (Common) growth rates for Medicofarma Biotech SA have been -43% over the past three years .

Back to Top